Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Next-Generation Agents Accelerate Advances in ALK+ and ROS1+ NSCLC

November 22nd 2019

Nisha A. Mohindra, MD, detailed current treatment strategies and some of the next-generation inhibitors that could shift sequencing approaches in ALK-positive and ROS1-positive non–small cell lung cancer.

Dr. Fidler on the FLAURA Trial in EGFR-Mutant NSCLC

November 22nd 2019

Mary J. Fidler, MD, discusses overall survival data of the phase III FLAURA trial looking at frontline osimertinib in EGFR-mutant non–small cell lung cancer.

Paradigm Shift Still Leaves Unanswered Questions in Stage III NSCLC

November 22nd 2019

Everett E. Vokes, MD, discusses remaining questions in stage III non–small cell lung cancer following the PACIFIC results.

Yale Radiation Oncologist Searches for the Elusive "Abscopal" Effect

November 21st 2019

Allison Campbell, MD, PhD, discusses the synergy between immune checkpoint inhibitors and radiation therapy and the challenges facing ongoing clinical development.

Dr. Feldman on Prophylactic Cranial Irradiation in SCLC

November 21st 2019

Lawrence E. Feldman, MD, discusses utilizing prophylactic cranial irradiation in limited-stage and extensive-stage small cell lung cancer.

Future of Molecular Testing in NSCLC Lies in Larger DNA and RNA Analysis

November 21st 2019

Jeremy Segal, MD, PhD, discusses pathologic considerations in non–small cell lung cancer and the evolving role of molecular testing.

Emerging Immunotherapy Combos Seek to Capitalize on the Powers of RT

November 20th 2019

A growing appreciation of the immunomodulatory properties of radiation therapy (RT) and their role in the rare, but highly sought-after “abscopal effect”—whereby localized RT elicits systemic antitumor effects—is fueling excitement in the radiation oncology field.

Improved OS Data Signal New Era With Immunotherapy in Small Cell Lung Cancer

November 20th 2019

Lawrence E. Feldman, MD, discusses the impact of the phase III data of the IMpower133 and CASPIAN trials, ongoing trials, and other updates in small cell lung cancer treatment.

Dr. Piotrowska on Treatment for EGFR-Mutant NSCLC

November 20th 2019

Zofia Piotrowska, MD, MHS, discusses treatment strategies for EGFR-mutant non–small cell lung cancer.

Up Front NGS Among Top Advances in Lung Cancer

November 19th 2019

Azadeh Namakydoust, MD, discusses recent advancements in lung cancer and what the future holds.

Dr. Namakydoust on the Use of Next-Generation Sequencing in Lung Cancer

November 18th 2019

Azadeh Namakydoust, MD, FACP, thoracic oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of next-generation sequencing (NGS) in lung cancer.

Dr. Levy on Molecular Drivers in NSCLC

November 15th 2019

Benjamin P. Levy, MD, discusses the identification of molecular drivers in non–small cell lung cancer.

Targeted Agents, Immunotherapy Transforming Treatment Across NSCLC Spectrum

November 15th 2019

Mark G. Kris, MD, discusses the impact of targeted therapy in patients with EGFR-mutant NSCLC and the encouraging activity that has been reported with checkpoint inhibitors in advanced squamous disease.

Dr. Owonikoko on Standard of Care for SCLC

November 15th 2019

Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.

Dr. Kelly on Determining Second-Line TKI in Lung Cancer

November 14th 2019

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.

Predictive, Prognostic Biomarkers Continue to Enhance Treatment Decisions in NSCLC

November 14th 2019

Isabel Preeshagul, DO, MBS, discusses encouraging updates with molecular drivers in non–small cell lung cancer and her advice to community oncologists treating patients.

Dr. Fidler on RELAY Trial Results in EGFR+ NSCLC

November 14th 2019

Mary J. Fidler, MD, discusses the results of the phase III RELAY trial in treatment-naïve patients with EGFR-mutant non–small cell lung cancer.

Shaping the Future in Lung Cancer

November 13th 2019

Rapid advancements are dramatically changing the lung cancer treatment landscape, creating challenges across the spectrum of care.

Dr. Kris on Search for Biomarkers in Advanced Squamous NSCLC

November 13th 2019

Mark G. Kris, MD, discusses the ongoing search for additional biomarkers in advanced squamous non–small cell lung cancer.

Dr. Stiles on Surgical Considerations in Lung Cancer

November 12th 2019

Brendon Stiles, MD, discusses considerations for surgery in lung cancer.